Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Nasopharyngeal Carcinoma
NCT02293356Phase 4Unknown
- Start
- Aug 2015
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nimotuzumab in nasopharyngeal carcinoma (NPC). Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02293356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293356.